Fractional CO2 laser could treat primary cutaneous amyloidosis effectively
A clinical trial determined that fractional CO2 laser treatments resulted in clinical and histological changes in rare skin lesions.
In a randomized clinical trial, researchers at Cairo University (Cairo, Egypt) determined that applying different modes of a fractional CO2 laser resulted in clinical and histological changes in primary cutaneous amyloidosis (PCA) lesions. PCA—a rare skin disease that results from accumulation of inappropriately folded proteins—has various treatments available, but none are considered curative or satisfactory.
In the study, 25 patients with PCA were treated—in four sessions at four-week intervals—with a fractional CO2 laser using superficial ablation and deep rejuvenation. Both modes yielded significant reduction of pigmentation, thickness, itching, and amyloid deposits.
Full details of the work appear in the journal Lasers in Surgery and Medicine; for more information, please visit http://dx.doi.org/10.1002/lsm.22361.
Follow us on Twitter, 'like' us on Facebook, connect with us on Google+, and join our group on LinkedIn